Hangzhou Biotest Biotech Co Ltd (688767) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hangzhou Biotest Biotech Co Ltd (688767) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥28.39 Million ≈ $4.15 Million USD) by net assets (CN¥2.34 Billion ≈ $342.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Hangzhou Biotest Biotech Co Ltd to measure how much of total assets are equity-financed.
Hangzhou Biotest Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hangzhou Biotest Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hangzhou Biotest Biotech Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Hangzhou Biotest Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hangzhou Biotest Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangyin Electrical Alloy Co Ltd
SHE:300697
|
0.018x |
|
Hubei Jiuzhiyang Infrared System Co Ltd
SHE:300516
|
0.011x |
|
Wuxi Huadong Heavy Machinery Co Ltd
SHE:002685
|
0.042x |
|
Strive Asset Management
NASDAQ:ASST
|
-0.029x |
|
Dogus Otomotiv Servis ve Ticaret AS
IS:DOAS
|
-0.041x |
|
Decai Decoration Co Ltd
SHG:605287
|
0.009x |
|
Lahav LR Real Estate Ltd
TA:LAHAV
|
0.011x |
|
MeiraGTx Holdings PLC
NASDAQ:MGTX
|
-8.050x |
Annual Cash Flow Conversion Efficiency for Hangzhou Biotest Biotech Co Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hangzhou Biotest Biotech Co Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see 688767 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.37 Billion ≈ $346.99 Million |
CN¥106.47 Million ≈ $15.58 Million |
0.045x | -15.92% |
| 2024-12-31 | CN¥2.41 Billion ≈ $353.00 Million |
CN¥128.83 Million ≈ $18.85 Million |
0.053x | -1.60% |
| 2023-12-31 | CN¥2.42 Billion ≈ $354.23 Million |
CN¥131.38 Million ≈ $19.23 Million |
0.054x | -80.22% |
| 2022-12-31 | CN¥2.56 Billion ≈ $374.94 Million |
CN¥703.21 Million ≈ $102.90 Million |
0.274x | -36.29% |
| 2021-12-31 | CN¥2.11 Billion ≈ $308.49 Million |
CN¥908.12 Million ≈ $132.89 Million |
0.431x | -57.22% |
| 2020-12-31 | CN¥443.02 Million ≈ $64.83 Million |
CN¥446.07 Million ≈ $65.27 Million |
1.007x | +394.07% |
| 2019-12-31 | CN¥125.95 Million ≈ $18.43 Million |
CN¥25.67 Million ≈ $3.76 Million |
0.204x | -5.51% |
| 2018-12-31 | CN¥98.15 Million ≈ $14.36 Million |
CN¥21.17 Million ≈ $3.10 Million |
0.216x | +142.81% |
| 2017-12-31 | CN¥79.63 Million ≈ $11.65 Million |
CN¥7.07 Million ≈ $1.04 Million |
0.089x | -- |
About Hangzhou Biotest Biotech Co Ltd
Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immun… Read more